Pfizer terminates development of two drugs

Manufacturing News, Source : TheManufacturer.com
Published : 01 Jul 2005 17:46

Pharmaceutical maker Pfizer today announced that it was stopping development of two drugs in the company's development pipeline, including a potential therapy for AIDS, due to unsatisfactory results with the drugs.

The AIDS drug, capravirine, is a drug under study for patients with HIV and AIDS who have failed on currently available antiretroviral therapies. Pfizer based the decision on results of two studies, which failed to show a statistically significant difference between standard triple-drug HIV therapies and the same therapy combined with capravirine.

Also, Pfizer and Altana Pharma have mutually agreed to terminate a collaboration between the two companies involving the development of Daxas, a drug for chronic obstructive pulmonary disease and asthma. Lack of effectiveness in reducing cough and shortness of breath cause the drug’s termination.

“The search for new and innovative medicines for the treatment of HIV/AIDS, COPD and asthma remains a priority for Pfizer and we will continue to invest in other research activities in these areas to address the needs of patients and health care providers,” said John LaMattina, president of Pfizer Global Research and Development.

Comments on this story

click here to add a comment